Skip to content
Sector Performance
% Price Change
All Sectors
-0.49%
Energy
+1.65%
Real Estate
+0.99%
Consumer Staples
+0.99%
Health Care
+0.24%
Health Care Equipment & Services
+0.24%
Pharmaceuticals, Biotechnology & Life Sciences
+0.25%
Financials
+0.14%
Utilities
+0.13%
Communication Services
-0.23%
Consumer Discretionary
-0.68%
Industrials
-0.88%
Materials
-1.07%
Information Technology
-1.29%
Data last updated as of 4:38 PM EDT 04/28/2026
* The weighted average of intraday total return

Latest Sector News

AstraZeneca’s Profit Climbs on Strong Sales of Cancer Drugs AstraZeneca Plc’s profit grew more than expected in the first quarter, bolstered by demand for its blockbuster cancer medicines.
AstraZeneca’s Profit Climbs on Strong Sales of Cancer Drugs
GSK Profit Beats Estimates on HIV, Cancer Medicines GSK Plc’s profit was higher than analysts expected in the first quarter, helped by the drugmaker’s specialty medicines for HIV, cancer and immune diseases.
GSK Profit Beats Estimates on HIV, Cancer Medicines
Haleon’s First-Quarter Sales Dragged Down by Weak Cold Season Haleon Plc’s first quarter was weaker than expected, hurt by lackluster demand for over-the-counter cold and flu medicines at the start of the year.
Haleon’s First-Quarter Sales Dragged Down by Weak Cold Season
RemeGen Focused on Growing Domestic Business
RemeGen Focused on Growing Domestic Business
Shaojing Tong, CFO at Chinese biotech firm RemeGen, discusses the company's first quarter results and shares his confidence in growth in the domestic market. The company's stock has outperformed all of its peers in the MSCI China Healthcare Index since the start of the year. (Source: Bloomberg)
More Sector News
GiGaSoft
Terms of ServiceTrademarksPrivacy Policy
CareersMade in NYCAdvertise
Ad Choices
Help©2026 Bloomberg L.P. All Rights Reserved.